Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761 ^®

• Main Authors: Nagaendran Kandiah, Paulus Anam Ong, Turana Yuda, Li Ling Ng, Kaysar Mamun, Reshma Aziz Merchant, Christopher Chen, Jacqueline Dominguez, Simeon Marasigan, Encarnita Ampil, Van Thong Nguyen, Suraya Yusoff, Yee Fai Chan, Fee Mann Yong, Orapitchaya Krairit, Chuthamanee Suthisisang, Vorapun Senanarong, Yong Ji, Ramesh Thukral, Ralf Ihl
• Other Authors: Can Tho University of Medicine and Pharmacy
• Format: Article
• Published: 2020
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/51940
• Institution: Mahidol University

© 2018 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd Background: The Ginkgo biloba special extract, EGb 761 ® has been widely used in the treatment of neuropsychiatric disorders, including Alzheimer’s disease (AD). Methods: To guide clinical practice in the Asian region, the Asian Clinical Expert Group on Neurocognitive Disorders compiled evidence-based consensus recommendations regarding the use of EGb 761 ® in neurocognitive disorders with/without cerebrovascular disease. Results: Key randomized trials and robust meta-analyses have demonstrated significant improvement in cognitive function, neuropsychiatric symptoms, activities of daily living (ADL) and quality of life with EGb 761 ® versus placebo in patients with mild-to-moderate dementia. In those with mild cognitive impairment (MCI), EGb 761 ® has also demonstrated significant symptomatic improvement versus placebo. World Federation of Societies of Biological Psychiatry guidelines list EGb 761 ® with the same strength of evidence as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) antagonists e.g. memantine (Grade 3 recommendation; Level B evidence). Only EGb 761 ® had Level B evidence in improving cognition, behaviour, and ADL in both AD and vascular dementia patients. Safety analyses show EGb 761 ® to have a positive risk-benefit profile. While concerns have been raised regarding a possible increased bleeding risk, several randomized trials and two meta-analyses have not supported this association. Conclusions: The Expert Group foresee an important role for EGb 761 ® , used alone or as an add-on therapy, in the treatment of MCI and dementias, particularly when patients do not derive benefit from acetylcholinesterase inhibitors or NMDA antagonists. EGb 761 ® should be used in alignment with local clinical practice guidelines.